Show simple item record

dc.contributor.authorAlkureishi, Lee W T
dc.contributor.authorBurak, Zeynep
dc.contributor.authorAlvarez, Julio A
dc.contributor.authorBallinger, James
dc.contributor.authorBilde, Anders
dc.contributor.authorBritten, Alan J
dc.contributor.authorCalabrese, Luca
dc.contributor.authorChiesa, Carlo
dc.contributor.authorChiti, Arturo
dc.contributor.authorde Bree, Remco
dc.contributor.authorGray, Harry W
dc.contributor.authorHunter, Keith
dc.contributor.authorKovacs, Adorjan F
dc.contributor.authorLassmann, Michael
dc.contributor.authorLeemans, C Rene
dc.contributor.authorMamelle, Gerard
dc.contributor.authorMcGurk, Mark
dc.contributor.authorMortensen, Jann
dc.contributor.authorPoli, Tito
dc.contributor.authorShoaib, Taimur
dc.contributor.authorSloan, Philip
dc.contributor.authorSorensen, Jens A
dc.contributor.authorStoeckli, Sandro J
dc.contributor.authorThomsen, Jorn B
dc.contributor.authorTrifiro, Giusepe
dc.contributor.authorWerner, Jochen
dc.contributor.authorRoss, Gary L
dc.date.accessioned2010-08-09T12:06:01Z
dc.date.available2010-08-09T12:06:01Z
dc.date.issued2009-11
dc.identifier.citationJoint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. 2009, 36 (11):1915-36 Eur. J. Nucl. Med. Mol. Imagingen
dc.identifier.issn1619-7089
dc.identifier.pmid19784646
dc.identifier.doi10.1007/s00259-009-1248-0
dc.identifier.urihttp://hdl.handle.net/10541/109282
dc.description.abstractInvolvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method of determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histological nodal staging and avoids over-treating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This article was designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. These guidelines were prepared by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial Committee.
dc.language.isoenen
dc.subjectMouth Canceren
dc.subjectOropharyngeal Canceren
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshHumans
dc.subject.meshLymph Nodes
dc.subject.meshMouth Neoplasms
dc.subject.meshOropharyngeal Neoplasms
dc.subject.meshSentinel Lymph Node Biopsy
dc.titleJoint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Plastic Surgery, University of Chicago Medical Center, Chicago, USA. lee_alkureishi@hotmail.comen
dc.identifier.journalEuropean Journal of Nuclear Medicine and Molecular Imagingen
html.description.abstractInvolvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method of determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histological nodal staging and avoids over-treating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This article was designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. These guidelines were prepared by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial Committee.


This item appears in the following Collection(s)

Show simple item record